|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Studies evaluating leptin levels in patients with first-episode psychoses (FEP) have been inconclusive, and apparently, the high levels of leptin reported in patients with schizophrenia may be associated with weight gain.
|
30660810 |
2019 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Lower leptin levels were associated with higher severity of suicidal behaviour in schizophrenia.
|
30848483 |
2019 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
An increase in leptin and insulin levels was observed for both schizophrenia patients (Cohen's d (d): 0.26 and 0.65, respectively) and MDD patients (d: 0.29 and 0.12, respectively) compared to their respective controls.
|
31230885 |
2019 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We previously found that blood C-reactive protein (CRP), interleukin-6 (IL-6), and leptin levels were predictors of current metabolic syndrome in schizophrenia.
|
31118157 |
2019 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Serum concentration of clozapine and fasting serum levels of des-acylated ghrelin, neuropeptide Y (NPY), agouti-related protein (AgRP), peptide YY (PYY(1-36)), cocaine- and amphetamine-regulated transcript (CART), leptin and obestatin were measured in 30 subjects with schizophrenia on clozapine monotherapy.
|
29275180 |
2018 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Despite the small sample and mostly negative findings, we encourage more work to use higher and repeated doses of oxytocin, and to further examine the effect of oxytocin on leptin in schizophrenia as this may be important for understanding both weight control and psychopathology.
|
29524451 |
2018 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
There were no statistically significant results when the c-reactive protein, adiponectin, leptin and irisin levels were compared between the schizophrenia and the control group (p>0.05).
|
29219062 |
2018 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
BMI, fasting insulin, cholesterol, triglyceride, LDL, ApoB and leptin were significantly increased in patients with schizophrenia after 8 weeks of olanzapine treatment.
|
29410009 |
2018 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Leptin, sTNF-R, CCL-3 and CCL-11 were significantly higher in SCZ.
|
28346888 |
2017 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The purposes of the present study were to quantitatively assess abdominal and liver fat in patients with schizophrenia on antipsychotic treatment and age- and body mass index (BMI)-matched healthy controls and to evaluate their associations with plasma leptin and adiponectin levels.
|
28315932 |
2017 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
<b>Data Sources:</b> MEDLINE, Google Scholar, Cochrane Database and PsycINFO databases were searched for articles containing all the following exploded MESH terms: schizophrenia [AND] antipsychotic agents/neuroleptics [AND] (weight gain [OR] lipids [OR] insulin [OR] leptin) [AND] treatment outcome.
|
29403343 |
2017 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The results of the present study do not support a major role of SNPs LEP rs7799039, ADIPOQ rs1501299 and HTR2C rs1414334 in the regulation of weight gain or association of serum levels of leptin and adiponectin and corresponding studied SNPs in patients with schizophrenia on clozapine treatment.
|
25284335 |
2015 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We investigated the associations of the LEP-2548A/G and HTR2C-759C/T polymorphisms with long-term clozapine-induced weight changes and baseline BMI in chronic patients with schizophrenia.
|
25304226 |
2014 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The role of leptin in atypical antipsychotic-induced metabolic dysfunction was explored by assessing the anthropometric and metabolic profile and the response to metformin (MET) of clozapine- (CLZ) treated schizophrenia patients according to their single nucleotide polymorphisms (SNPs) in the leptin promoter (LEP2548/GA) and leptin receptor (LEPR Q223R) genes.
|
20591628 |
2010 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia.
|
18515891 |
2008 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
LHGDN |
Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophrenia.
|
17285096 |
2007 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
PSYGENET |
Thus, variation in the leptin gene may be a risk factor for weight gain in male patients with schizophrenia on long-term clozapine treatment.
|
17502770 |
2007 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
These findings confirm the importance of two genetic factors associated with long-term antipsychotic-induced weight increases in schizophrenia, and implicate a role for leptin in the 5-HT receptor-mediated weight regulation.
|
15864111 |
2005 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
PSYGENET |
Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis.
|
15864111 |
2005 |